

May 22, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Friday, May 22, 2026

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject; we, Zota Health Care Limited (“the Company”), would like to inform you that the Board of Directors of the Company in its Meeting held on Friday, May 22, 2026 at 11:00 A.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboj, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have *inter alia*, discussed and approved the following businesses:

1. Considered and approved Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2026 along with the Audit Reports thereon. Financial Results and Audit Reports are enclosed herewith (**Annexure-1**).

We would like to inform you that M/s. Pradeep K. Singhi & Associates, Chartered Accountants, Statutory Auditors of the Company, have issued the Audit Reports with Unmodified opinion. Further, Standalone and Consolidated Audited Financial Results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company’s website at www.zotahealthcare.com.

2. Recommended final dividend at the rate of 10% i.e. Re. 1/- per equity share of Rs. 10/- each for the financial year 2025-26, subject to the approval of shareholders at the ensuing Annual General meeting of the Company.

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

3. Approved for acquisition of 39,794 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as **(Annexure-2)**.

The Board meeting concluded at 6:15 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya

(Company Secretary & Compliance Officer)

Place: Surat

Encl.: a/a

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
ZOTA HEALTH CARE LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly and year to date financial results of **ZOTA HEALTH CARE LIMITED** (the "Company") for **the quarter and year ended March 31, 2026** ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net-profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "*Auditor's Responsibilities for the Audit of the Standalone Financial Results*" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our

opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published figures of the year-to-date (nine months) ended December 31, 2025 , which were subjected to limited review, as required under the Listing Regulations.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

Date: 22-05-2026

Place: Surat

Pradeep Kumar Singhi
(Partner)
UDIN: 26024612YVFGAG9199

Particulars	Quarter Ended			Year Ended	
	31-03-26 (Audited)	31-12-25 (Unaudited)	31-03-25 (Audited)	31-03-26 (Audited)	31-03-25 (Audited)
I. Revenue from Operations	12070.05	10887.55	7793.25	40700.72	25727.61
II. Other Income	410.33	379.76	149.53	1340.18	462.34
III. Total Income	12480.38	11267.31	7942.78	42040.91	26189.94
IV. Expenses:					
Cost of Materials Consumed	360.44	606.62	609.03	1746.43	1622.76
Purchases of Stock-in-Trade	8930.20	6491.41	5577.95	23674.65	15530.50
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	0.00	0.00			
	(2385.93)	(1038.35)	(1445.69)	(2550.99)	(1614.25)
Employee Benefit Expenses	1548.10	1318.28	886.75	4889.32	3114.97
Finance Costs	8.34	4.57	7.93	25.26	105.59
Depreciation / Amortisation and Depletion Expense	125.33	99.38	94.37	395.43	317.11
Other Expenses	3082.76	2682.80	1770.49	9785.45	5928.92
Total Expenses	11669.23	10164.70	7500.83	37965.54	25005.61
V. Profit before Exceptional items and tax from continuing operations (III-IV)	811.15	1102.60	441.95	4075.36	1184.33
VI. Exceptional Items	(98.96)			(98.96)	
VII. Profit/(loss) before tax	712.19	1102.60	441.95	3976.40	1184.33
VIII. Tax Expense:					
(1) Current tax	264.00	275.50	203.91	1095.36	338.13
(1.1) I.T. & DD Tax Provision Created Short/ excess	0.00	(10.95)	(0.00)	(10.95)	(2.49)
(2) Deferred Tax	160.69	(237.55)	22.29	(101.34)	13.03
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	608.87	600.50	260.33	2790.66	861.72
X. Profit/(loss) before tax from discontinued operations			-		
XI. Tax Expense of discontinued Operations			-		
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)			-		
XIII. Profit/ (Loss) for the period	608.87	600.50	260.33	2790.66	861.72
XIV. Other Comprehensive Income					
A (i) Items that will not be reclassified to Statement of profit and loss	31.02	35.88	6.13	50.81	19.11
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(7.81)	(9.03)	(1.54)	(12.79)	(4.81)
B (i) Items that will be reclassified to Statement of profit and loss					
(ii) Income Tax relating to items that will be reclassified to profit and loss					
Other comprehensive income for the period, net of tax	23.21	26.85	4.58	38.02	14.30
Total comprehensive income for the period (XIII + XIV)	632.09	627.35	264.91	2828.68	876.01
Paid-up Equity Share Capital	3463.26	3377.39	2863.50	3463.26	2863.50
Other Equity				85356.94	28873.37
Earnings per equity share of face value of ₹ 10 each					
(1) Basic (in ₹)	1.77	1.92	0.92	8.48	3.16
(2) Diluted (in ₹)	1.77	1.87	0.86	8.48	2.91

* denotes figures less than a lakh

For and on behalf of the Board


 (Whole Time Director)
 Himanshu M. Zota
 (Din : 01097722)


 (Managing Director)
 Moxesh K. Zota
 (Din : 07625219)


 Company Secretary
 Ashvin Variya
 Date: 22-05-2026
 Place : Surat


 Chief Financial Officer
 Viral Mandviwala


 Group CEO
 Sujit Paul



For Pradeep K. Singhi & Associates
 Chartered Accountants
 Firm No. 0126027W

Pradeep Kumar Singhi
 (Partner)
 M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
 Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
 Email: info@zotahealthcare.com
 Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
 Nr. Sachin Railway Station, Sachin,
 Surat - 394 230 (Guj) India
 Ph: +91 261 2397122

healthcare ltd.	PARTICULARS	For the Year Ended on 31st March, 2026	For the Year Ended on 31st March, 2025
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax as per Statement of Profit and Loss	4075.36	1184.33
	Adjusted for:		
	Exceptional items	(98.96)	-
	(Profit) on sale of Property, Plant and Equipment	0.00	0.00
	Depreciation / Amortisation and Depletion Expense	395.43	317.11
	Employee stock option expense	290.22	59.47
	Finance Costs	12.35	49.76
	Interest Income	(1230.96)	(435.06)
	Operating Profit before Working Capital Changes and other adjustments:		
		3443.44	1175.62
	Adjusted for:		
	Inventories	(2362.14)	(1949.39)
	Trade Receivables	(7254.11)	(2932.66)
	Trade Payables	3022.00	1538.51
	Other Current Liabilities and Provisions	1343.62	951.02
	Provisions - Non-Current	69.08	61.56
	Current Financial Assets	(68.64)	(523.16)
	Other Current Assets	(1659.40)	(202.50)
	Changes in Working Capital	(6909.57)	(3056.61)
	Cash Generated from Operations	(3466.13)	(1880.99)
	Direct Taxes Paid	(1097.19)	(340.45)
	Net Cash Flow from/(used in) Operating Activities	(4563.32)	(2221.44)
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Add: Adjustment for		
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets	(2054.56)	(425.94)
	Proceeds from disposal of Property, Plant and Equipment		
	Purchase of Intangible Assets		
	Proceeds from disposal of Intangible Assets		
	Decrease in Long Term Loans & Advances	(7544.77)	(3846.89)
	Interest Received	1230.96	435.06
	Non-current Investments	(43164.01)	(10946.95)
	Net Cash Flow from/(used in) Investing Activities	(51532.38)	(14784.73)
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Add: Adjustment for		
	Proceeds from/(Repayment of) Long Term Borrowings		
	Proceeds from Issue of Equity Share Capital	599.76	278.77
	Increase in Securities Premium Reserve	58770.65	14835.71
	Less: Adjustment for		
	Money received/adjusted against Share warrants	(4303.85)	3783.45
	Increase in short-term Borrowings	2169.17	(1447.21)
	Finance Costs paid	(12.35)	(49.76)
	Share issue expenses	(795.69)	
	Dividend Paid	(306.44)	(274.08)
	Net Cash Flow from / (used in) Financing Activities	56121.25	17126.88
	Net Increase/(Decrease) in Cash & Cash Equivalents	25.55	120.71
	Opening Balance of Cash and Cash Equivalents	134.99	14.28
	Closing Balance of Cash and Cash Equivalents	160.53	134.99

The accompanying notes are an integral part of the financial statements.

For and on behalf of the Board


Himanshu M. Zota

(Whole Time Director)
(Din : 01.09.7722)


Manish K. Zota

(Managing Director)
(Din : 07.62.5219)





Ashvin Variya
Company Secretary



Viral Mandviwala
Chief Financial Officer



Sujit Paul
Group CEO

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Date: 22-05-2026
Place: Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
**The Board of Directors of
ZOTA HEALTH CARE LIMITED**

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **ZOTA HEALTH CARE LIMITED** ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for **the quarter and year ended March 31, 2026** ("the Statement"), attached herewith, being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements of subsidiaries, the Statement:

- a. includes the results of the following entities:
 - Zota Health Care Limited (Parent)
 - Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
 - Davaindia Health Mart Limited (Wholly Owned Subsidiary)
 - Zota Nex Tech Limited (Wholly Owned Subsidiary)
 - KMHP Ventures Limited (Wholly Owned Subsidiary)
 - Curexis Ventures Private Limited (Wholly Owned Subsidiary)
 - Everyday Herbal Beauty Care Private Limited (Subsidiary)
 - Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net-profit/(loss) and other comprehensive income) and other financial information of the Group for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical

requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net-profit and other comprehensive income and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The Statement includes the audited Financial Statements of 7 subsidiaries, whose financial statements reflect total assets of Rs. 66105.42 Lakhs as at March 31, 2026 and total revenues of Rs. 28820.74 Lakhs, total net loss of Rs. 10579.85 lakhs and total comprehensive loss of Rs. 10464.70 lakhs and cash inflows (net) Rs. 9169.87 lakhs for the year ended March 31 2026, as considered in the consolidated financial results, which have been audited by their respective independent auditors.

The independent auditors' reports on the financial statements of these entities have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results certified by the Board of Directors.

Further, in addendum to paragraph 1 of this report, we report that the figures for the quarter ended March 31, 2026 represents the derived figures between the audited figures of the financial year ended March 31, 2026 and the published figures of the year-to-date (nine months) ended December 31, 2025 , which were subjected to limited review.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

Date: 22-05-2026


Place: Surat


Pradeep Kumar Singhi
(Partner)
UDIN: 26024612EYPFSF3965

Particulars	Quarter Ended			Year Ended	
	31-03-26	31-12-25	31-03-25	31-03-26	31-03-25
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	16317.53	14295.14	9727.46	53865.75	29297.48
II. Other Income	320.80	171.69	100.15	743.75	206.80
III. Total Income	16638.33	14466.83	9827.61	54609.50	29504.28
IV. Expenses:					
Cost of Materials Consumed	360.44	606.62	609.03	1746.43	1622.76
Purchases of Stock-in-Trade	10797.91	7703.59	6221.19	28534.72	16257.53
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(5196.64)	(2632.89)	(2042.73)	(8884.30)	(4149.96)
Employee Benefit Expenses	5443.49	5252.46	2593.62	17832.98	8606.62
Finance Costs	532.25	497.14	345.80	1736.11	1078.34
Depreciation / Amortisation and Depletion Expense	2701.13	2225.55	1431.50	8245.31	4319.61
Other Expenses	4041.96	3409.48	2099.69	12781.94	7533.82
Total Expenses	18680.53	17061.94	11258.09	61993.19	35268.71
V. Profit before Exceptional items and tax from continuing operations (III-IV)	(2042.20)	(2595.11)	(1430.49)	(7383.69)	(5764.43)
VI. Exceptional Items	(599.98)	0.00	-	(599.98)	-
VII. Profit/(loss) before tax	(2642.18)	(2595.11)	(1430.49)	(7983.67)	(5764.43)
VIII. Tax Expense:					
(1) Current tax	264.00	269.30	203.91	1095.36	338.13
(1.1) I.T. & DD Tax Provision Created Short/ excess	0.00	(10.95)	(0.00)	(10.95)	(2.49)
(2) Deferred Tax	1459.99	(110.92)	345.54	1660.34	426.19
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1446.19)	(2964.38)	(1288.86)	(7407.74)	(5673.89)
X. Profit/(loss) before tax from discontinued operations	0.00	-	-	-	-
XI. Tax Expense of discontinued Operations	0	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	0	-	-	-	-
XIII. Profit/ (Loss) for the period	(1446.19)	(2964.38)	(1288.86)	(7407.74)	(5673.89)
XIV. Other Comprehensive Income					
A (i) Items that will not be reclassified to Statement of profit and loss	103.22	115.18	15.89	204.36	40.31
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(25.86)	(28.86)	(3.98)	(51.19)	(10.11)
B (i) Items that will be reclassified to Statement of profit and loss	(0.00)	*	(0.01)	*	(0.05)
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	*	*	*	0.01
Other comprehensive income for the period, net of tax	77.36	86.32	11.90	153.17	30.16
Total comprehensive income for the period (XIII + XIV)	(1368.83)	(2878.06)	(1276.96)	(7254.56)	(5643.73)
Profit attributable to:					
Owners of the parent	(1416.82)	(2950.32)	(1289.04)	(7393.61)	(5639.84)
Non-controlling interest	(29.37)	(14.06)	0.18	(14.13)	(34.05)
Other comprehensive income attributable to:					
Owners of the parent	77.36	86.32	11.90	152.42	30.16
Non-controlling interest	0.00	0.00	-	-	-
Total Comprehensive Income attributable to:					
Owners of the parent	(1339.47)	(2864.00)	(1277.14)	(7241.19)	(5609.68)
Non-controlling interest	(29.37)	(14.06)	0.18	(14.13)	(34.05)
Paid-up Equity Share Capital	3463.26	3377.39	2863.50	3463.26	2863.50
Other Equity				64481.81	19504.98
Earnings per equity share of face value of ₹ 10 each					
(1) Basic (in ₹)	-4.13	-9.44	(4.57)	(22.46)	(20.68)
(2) Diluted (in ₹)	-4.13	-9.21	(4.28)	(22.46)	(19.06)

* denotes figures less than a lakh

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Whole Time Director)
Moxesh K. Zota
(Din : 07625219)



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612


Company Secretary
Ashvin Variya
Date: 22-05-2026
Place : Surat


Chief Financial Officer
Viral Mandviwala


Group CEO
Sujit Paul

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352


Plant :


Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

healthcare ltd.		(Amount ₹ in Lakhs)	
	PARTICULARS	For the year ended March 31, 2026	For the year ended March 31, 2025
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax as per Statement of Profit and Loss	(7383.69)	(5764.43)
	Adjusted for:		
	Exceptional items	(599.98)	-
	Depreciation / Amortisation and Depletion Expense	8245.31	4319.61
	Employee stock option expense	290.22	59.47
	Loss on sale of Property Plant & Equipment	-	0.81
	Finance Costs	1736.11	1078.34
	Interest Income	(889.98)	(343.44)
	Operating Profit before Working Capital Changes	1397.99	(649.65)
	Adjusted for:		
	Inventories	(8695.45)	(5191.77)
	Trade Receivables	(3301.60)	(1325.76)
	Trade Payables	6219.57	879.50
	Other Current Liabilities and Provisions	2807.03	1860.37
	Provisions - Non-Current	384.20	231.89
	Current Financial Assets	(1993.93)	(39.02)
	Other Current Assets	(4113.82)	(413.75)
	Changes in Working Capital	(8693.98)	(3998.54)
	Cash Generated from Operations	(7295.99)	(4648.19)
	Taxes Paid	(1146.54)	(348.24)
	Net Cash Flow from/(Used in) Operating Activities (A)	(8442.54)	(4996.43)
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets	(11293.15)	(4597.78)
	Proceeds from disposal of Intangible Assets	-	-
	Proceeds from disposal of Property, Plant and Equipment	-	1.10
	Interest Received	889.98	343.44
	Non-current Investments	(20953.17)	(4965.35)
	Net Cash Flow (Used in) Investing Activities (B)	(31356.34)	(9218.59)
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from Issue of Equity Share Capital	599.76	278.77
	Increase in Securities Premium Reserve	58770.65	14835.71
	Money received/adjusted against Share warrants	(4303.85)	3783.45
	Increase in short-term Borrowings	2174.60	(1406.72)
	Principal payment of lease liability	(5546.09)	(2172.02)
	Interest payment of lease liability	(1387.46)	(826.51)
	Finance Costs	(348.65)	(241.73)
	Loans	137.46	499.48
	Share issue expenses	(795.69)	0.00
	Dividend Paid	(306.44)	(274.08)
	Net Cash Flow from / (Used in) Financing Activities (C)	48994.29	14476.35
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	9195.41	261.34
	Effect of Exchange differences on cash and cash equivalents held in foreign currency	0.09	0.10
	Opening Balance of Cash and Cash Equivalents	361.90	100.47
	Closing Balance of Cash and Cash Equivalents	9557.41	361.91

As per our report of even date

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612


Ashvin Variya
Company Secretary


Viral Mandviwala
Chief Financial Officer


Sujit Paul
Group CEO

Date: 22-05-2026
Place: Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Particulars	Standalone		Consolidated	
	As at 31st March, 2026 Audited	As at 31st March, 2025 Audited	As at 31st March, 2026 Audited	As at 31st March, 2025 Audited
ASSETS				
(1) Non-Current Assets				
Property, plant and equipment	3032.70	845.61	14041.17	5598.94
Right-of-use assets	-	-	22435.93	12538.11
Intangible Assets	409.24	379.62	433.99	401.37
Capital work-in-progress	0.00	557.58	171.06	557.58
Intangible assets under development	-	-	1375.41	90.25
Financial Assets				
(i) Investments	54787.97	11623.96	26388.47	5435.30
(iii) Loans	13466.73	5921.96	16.16	11.02
Deferred tax assets (Net)	(85.68)	15.66	2526.41	865.22
Other Non-current assets	-	-	-	-
Total Non-Current assets	71610.96	19344.38	67388.60	25497.79
(2) Current Assets				
Inventories	8317.67	5955.53	19263.83	10568.38
Financial Assets				
(i) Trade Receivables	17557.99	10303.88	7351.76	4050.15
(ii) Cash and Cash Equivalents	0.70	0.52	776.77	213.21
(iii) Bank balance other than cash and cash equivalents	159.84	134.46	8780.64	148.70
(iv) Loans	1862.42	1793.78	3692.98	1699.06
Other Current Assets	2099.12	439.73	5850.57	1736.76
Total Current assets	29997.73	18627.91	45716.55	18416.26
Total Assets	101608.69	37972.29	113105.14	43914.05
EQUITY AND LIABILITIES				
(1) Equity				
(i) Equity Share capital	3463.26	2863.50	3463.26	2863.50
(ii) Other Equity	85356.94	28873.37	65885.67	19504.98
Non-controlling interest	-	-	267.63	347.00
Total Equity (Refer Note 1)	88820.20	31736.87	69616.56	22715.48
(2) Liabilities				
Non-Current Liabilities				
Financial Liabilities				
(i) Borrowings	-	-	636.94	499.48
(ii) Lease liabilities	-	-	18357.94	10255.49
Provisions	248.42	179.34	766.42	382.21
Total non-current liabilities	248.42	179.34	19761.30	11137.19
Current liabilities				
Financial Liabilities				
(i) Borrowings	2189.64	20.46	2235.56	60.95
(ii) Lease liabilities	-	-	5813.50	3144.45
(ii) Trade payables	-	-	0.00	-
- Total outstanding dues of micro enterprises and small enterprises	2146.29	1248.17	2479.38	1248.17
- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	5498.32	3374.44	7980.27	2991.91
Other Current liabilities	978.88	759.56	1200.62	1008.34
Provisions	1726.94	653.45	4017.95	1607.55
Total current liabilities	12540.06	6056.08	23727.28	10061.38
Total Liabilities	12788.49	6235.41	43488.58	21198.57
Total Equity and Liabilities	101608.69	37972.29	113105.14	43914.05

For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)



(Managing Director)
Moxesh K. Zota
(Din : 07625219)



Company Secretary
Ashvin Variya



Chief Financial Officer
Viral Mandviwala



Group CEO
Sujit Paul



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Date: 22-05-2026
Place : Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter and year ended March 31, 2026 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 22, 2026.
2. The Financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The figures for quarter ended March 31, 2026 are balancing figures between the audited figures of the financial year ended March 31, 2026 and the published figures of the year-to-date (nine months) ended December 31, 2025, which were subjected to limited review report.
4. The Statutory Auditors have provided Standalone and Consolidated Audit Reports for the quarter and year ended March 31, 2026 with Unmodified option.
5. The Board of Directors has recommended dividend at the rate of 10% i.e. Re. 1/- per equity share of Rs. 10/- each for the financial year 2025-26, which is subject to approval of the members in ensuing Annual General Meeting.
6. The Company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
7. The Consolidated results include the result of following companies:
 - A) Wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - iv) Curexis Ventures Private Limited
 - v) KMHP Ventures Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Limited
 - ii) Everyday Herbal Beauty and Wellness Care Private Limited
8. In the Consolidated financial results, the Group has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 21629.95 lakhs and a corresponding Lease Liability of Rs. 23338.63 lakhs as at March 31, 2026. The impact of this on the consolidated profit for the quarter and year ended March 31, 2026 is Rs. 178.44 lakhs and Rs. 892.18 lakhs respectively.

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122



9. During the quarter, upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has issued equity shares upon conversion of warrants as below:

Date of Allotment	No. of Equity Shares Issued
January 02, 2026	1,07,556
January 20, 2026	1,79,169
February 10, 2026	5,71,961

10. During the year, the Company has granted 16,394 stock options under Zota Health Care - Employee Stock Option Plan 2022' ("ZHL ESOP 2022"). As on March 31, 2026, the Company has on cumulative basis granted 1,27,124 stock options under Zota Health Care - Employee Stock Option Plan 2022. Out of the said options granted, 4,000 options have been unvested and stands cancelled. Accordingly, the total unexercised options till date are 1,23,124 options under ZHL ESOP 2022. Further, the options granted are yet to be exercised.
11. During the quarter, Company has made investments of:
- Rs. 10.00 lakhs by subscribing 1,00,000 equity shares of M/s KMHP Ventures Limited, at Rs. 10/- per equity share.
 - Rs. 16999.96 lakhs by subscribing 3,95,348 equity shares of M/s Davaindia Health Mart Limited through right issue basis, at a price of Rs. 4,300/- (including premium of Rs. 4,290/-) per equity share.
 - Rs. 1.00 lakh by acquiring 10,000 equity shares of M/s Curexis Ventures Private Limited, at Rs. 10/- per equity share.
 - Rs. 2529.56 lakhs by subscribing 58,827 equity shares of M/s Davaindia Health Mart Limited through right issue basis, at a price of Rs. 4,300/- (including premium of Rs. 4,290/-) per equity share.
 - Rs. 1947.00 lakhs by subscribing 1,18,00,000 equity shares of M/s Everyday Beauty Care Limited through right issue basis, at a price of Rs. 16.50/- (including premium of Rs. 6.50/-) per equity share.
12. Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in the wages by Rs. 599.98 lakhs on the consolidated basis primarily arising due to change in the definition of "wages" for employees. Considering the materiality and non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Item" in the standalone and consolidated financial results for the quarter and year ended March 31, 2026.
13. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.



May 22, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

Dear Sir/ Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 in respect of Audit Reports with unmodified opinion

I, Himanshu Muktilal Zota, Whole-time Director of Zota Health Care Limited, hereby declare that M/s Pradeep K. Singhi & Associates, Chartered Accountants (Firm Reg. No. 0126027W), Statutory Auditors of the Company, have issued Audit Reports with Unmodified opinion on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

This declaration is being given in accordance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended, and SEBI Circular No.: CIR/CFD /CMD/56/2016 dated May 27, 2016.

Kindly take this on your record.

Thanking you,

Yours faithfully,
For **Zota Health Care Limited**



Himanshu Muktilal Zota
(Whole-time Director)
DIN: 01097722



Place: Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc.	<p>i. Name of the Target Entity: Davaindia Health Mart Limited (“DIHML”)</p> <p>ii. Business of the Target Entity: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy.</p> <p>iii. Financial details: As per the audited financial statements for the Financial Year 2025-26, the turnover of DIHML was Rs. 267.71 crores and the total paid up share capital was Rs. 2.71 crores.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition does not fall within related party transactions. The promoter/ promoter group/ group companies do not have any interest in DIHML.
Industry to which the entity being acquired belongs	Pharmaceutical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company has made further investment in DIHML as a part of strategic investment, expansion of COCO stores of Davaindia by WOS and working capital requirements of WOS. Post to this acquisition, DIHML continues to remain as the WOS of the Company.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	On May 22, 2026, the Company has acquired the said 39,794 equity shares of DIHML.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of equity shares.
Cost of acquisition or the price at which the shares are acquired	Cost of acquisition for the right issue of 39,794 equity shares is Rs. 5,075/- per equity share (including premium of Rs. 5,065/- per equity share) aggregating to Rs. 20,19,54,550/-.
Percentage of shareholding / control acquired and / or number of shares acquired	The Company has further acquired 39,794 equity shares of DIHML. Post to this acquisition, the DIHML continues to remain as the WOS of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>DIHML was incorporated on January 01, 2020, domiciled in India; operating COCO stores of Davaindia Generic Pharmacy with 1,656 stores as at March 31, 2026 and offering 2000+ SKUs inclusive of Medicines, Ayurvedic, Cosmetics, Nutraceutical and OTC products.</p> <p>During last three financial years, the details of turnover of DIHML were as follows: FY 2025-26 Rs. 267.71 crores FY 2024-25 Rs. 109.93 crores FY 2023-24 Rs. 44.77 crores</p>